Acute & MSK · Full case

Neuropathic Pain

NICE CG173AmitriptylineDuloxetine
NP
Neuropathic Pain · Clinical Reasoning Framework v2
GP & SCA · NICE CG173 · Amitriptyline · Duloxetine · Gabapentin · Pregabalin · NOT NSAIDs · NOT Paracetamol alone · Renal dose adjustment
DN4 ≥4/10 = neuropathic painThe Douleur Neuropathique 4 (DN4) questionnaire is the most widely used validated screening tool for neuropathic pain. It contains 10 items across 4 questions: (1) burning; painful cold; electric shock; (2) tingling; pins and needles; numbness; itching; (3) hypoaesthesia to touch; hypoaesthesia to prick; (4) allodynia to brushing. Each “yes” = 1 point; score ≥4/10 = neuropathic pain (sensitivity 83%; specificity 90%). Use at first presentation to confirm neuropathic mechanism and at follow-up to track treatment response. PainDETECT (9 items) and LANSS (24 points; ≥12 = neuropathic) are validated alternatives. Document the score in the clinical notes.
First-line: amitriptyline; duloxetine; gabapentin; or pregabalinNICE CG173 (2020): offer one of four first-line drugs for neuropathic pain in non-specialist settings. (1) Amitriptyline 10mg OD at night; titrate to 25–75mg OD. (2) Duloxetine 30mg OD for 1 week; increase to 60mg OD; especially for diabetic neuropathy with comorbid depression. (3) Gabapentin 300mg OD day 1; 300mg BD day 2; 300mg TDS day 3; titrate up to 3600mg/day; Schedule 3 CD; dose-adjust for renal impairment. (4) Pregabalin 150mg/day in divided doses; titrate to 300mg/day (maximum 600mg/day); Schedule 3 CD; dose-adjust for renal impairment. IMPORTANT: NSAIDs; paracetamol alone; and codeine are NOT effective for pure neuropathic pain — and MUST NOT be the primary treatment. These are for nociceptive (tissue damage) pain; not for damaged nerve pain.
Duloxetine: dual indication — neuropathic pain + depressionDuloxetine (SNRI) is specifically licensed for diabetic peripheral neuropathic pain and is NICE CG173 first-line. Its dual mechanism — descending pain modulation via noradrenaline + serotonin — also makes it effective for depression, which co-exists with chronic neuropathic pain in 30–60% of cases. When comorbid depression is present (PHQ-9 ≥10) and the neuropathic pain cause is diabetic neuropathy: duloxetine is the ideal first choice because it addresses both conditions simultaneously. Amitriptyline (TCA): effective for neuropathic pain and sleep disruption; also has antidepressant properties at higher doses. Choice depends on: tolerability; comorbidity; previous treatment; renal function (gabapentinoids must be dose-adjusted; duloxetine avoided in severe renal impairment).
Gabapentinoids: Schedule 3 CD — renal dose adjustment essentialGabapentin and pregabalin are both Schedule 3 Controlled Drugs (April 2019): require a full CD prescription; 28-day maximum supply; safe custody requirements apply in some settings. Renal dose adjustment is ESSENTIAL because both drugs are renally excreted: eGFR 30–59: reduce dose by approximately 50%; eGFR 15–29: reduce by approximately 75%; eGFR <15 or dialysis: specialist advice. Prescribing full-dose gabapentin to a patient with eGFR 30 is a potentially dangerous error. Always check eGFR before prescribing. Side effects: sedation; dizziness; weight gain; peripheral oedema; dependence risk. Taper when discontinuing (withdrawal seizures reported). IMPORTANT: gabapentinoids ARE first-line for neuropathic pain (NICE CG173) but are NOT recommended for non-specific LBP (NICE NG59) — the distinction is the clinical diagnosis, not the drug.
Trigeminal neuralgia: carbamazepine first-line (not amitriptyline)Trigeminal neuralgia (TN) is a special case: NICE CG173 recommends carbamazepine as first-line — not amitriptyline or gabapentinoids. Carbamazepine 100mg BD initially; titrate to 200mg TDS–QDS; sodium levels monitored; liver function; FBC (agranulocytosis risk); hyponatraemia (SIADH). TN features: unilateral; lancinating (electric shock-like); extremely brief duration (seconds to minutes); triggered by touch; eating; speaking; cold air; never present at night (differentiates from other neuropathic pain). Referral to neurology if: diagnosis uncertain; carbamazepine ineffective or not tolerated; or surgical treatment considered (microvascular decompression; MVD — highly effective).
Treatment target: 30–50% pain reduction (not elimination)A critical communication point with patients: neuropathic pain drugs do not usually eliminate pain completely. NICE CG173 and pain medicine literature: the target is a 30–50% reduction in pain intensity (measured on NRS 0–10). A patient who starts at 8/10 and achieves 4/10 has had a clinically meaningful response. This must be explained at the outset to set realistic expectations and prevent premature discontinuation (“the tablets aren’t working because I still have some pain”). Response assessment: 4–8 weeks on an adequate titrated dose. If no response at 8 weeks on optimal dose: switch to another first-line agent; if second agent fails: refer to pain clinic. Adequate dose trial before switching is important — under-dosed amitriptyline (10mg for 8 weeks without titration) is not an adequate trial.
PHQ-9 at every review — depression in 30–60% of chronic neuropathic painDepression co-exists with chronic neuropathic pain in 30–60% of patients. The relationship is bidirectional: depression amplifies pain perception (central sensitisation; reduced descending pain inhibition); chronic pain causes depression through sleep disruption; functional limitation; social isolation; and loss of identity. Treating depression alongside neuropathic pain significantly improves pain outcomes — which is why duloxetine’s dual mechanism is clinically advantageous. PHQ-9 must be administered at first presentation and at each review. PHQ-9 ≥10: depression treatment alongside neuropathic pain management — duloxetine as dual-indication agent; or separate antidepressant if gabapentin/pregabalin chosen for pain. Suicidality (PHQ-9 Q9 ≥1): urgent mental health assessment.
Post-herpetic neuralgia: topical options availablePost-herpetic neuralgia (PHN) has topical treatment options not available for other neuropathic pain types: (1) Topical capsaicin 0.075% cream: depletes substance P from peripheral sensory neurons; apply to affected area 3–4 times daily; initial burning sensation; takes 4–6 weeks; not for mucous membranes or broken skin. (2) Lidocaine 5% medicated plasters (Versatis): licensed for PHN; maximum 3 plasters for 12 hours in 24; minimal systemic absorption; apply to intact skin; particular benefit in patients with allodynia (where topical treatment avoids systemic side effects). (3) Capsaicin 8% high-strength patch (Qutenza): specialist-use only; dramatic reduction in PHN pain (30–40% mean reduction); clinic application (30–60 minutes); effective for up to 3 months. All systemic agents (amitriptyline; gabapentin; pregabalin) are also effective for PHN.
📋 Clinical Stem — Neuropathic Pain
Mrs. Patricia Osei, 67, retired teacher with 12-year type 2 diabetes, presenting with 6 months of burning, shooting foot pain worse at night, unresponsive to paracetamol and ibuprofen, tearful and not sleeping
Mrs. Patricia Osei, 67, retired teacher, attends with a 6-month history of burning pain in both feet, worse at night and disrupting her sleep. She describes the pain as “like walking on hot coals” with intermittent shooting sensations and an electric shock feeling at times. She has type 2 diabetes diagnosed 12 years ago; HbA1c is 62 mmol/mol (last checked 3 months ago); she is on metformin 1g BD and sitagliptin 100mg OD. She has been taking paracetamol 1g QDS and ibuprofen 400mg TDS for the last 3 months with little benefit. She is tearful, says the pain is affecting her sleep and her quality of life, and she cannot do her daily walks any more. Her recent PHQ-9 score is 12. She is worried that her diabetes is “getting a lot worse” and she is frightened about what that means.
This stem tests the ability to diagnose diabetic peripheral neuropathy; explain why NSAIDs and paracetamol are not effective for neuropathic pain; choose the correct first-line agent (duloxetine is ideal given comorbid depression); set realistic treatment expectations (30–50% reduction, not elimination); and address the patient’s fear of progressive diabetes complications. The SCA challenge is Mrs. Osei’s belief that “stronger painkillers” are the solution and her question about whether her diabetes is getting worse.
Scenario A — Diabetic peripheral neuropathy (Mrs. Osei’s scenario) Burning; shooting; electric shock; feet bilateral; worse at night; DM history; HbA1c suboptimal. PHQ-9 ≥10. First-line: duloxetine 30mg OD → 60mg OD (dual indication: neuropathic pain + depression). Alternatively: amitriptyline 10mg at night (if depression not prominent or duloxetine contraindicated). Add: foot care advice; podiatry; diabetes team referral for HbA1c optimisation.
Scenario B — Post-herpetic neuralgia Unilateral; dermatomal; burning; allodynia; follows shingles rash (may be weeks to months after). First-line: amitriptyline; gabapentin; or pregabalin. Topical options: lidocaine 5% patches (Versatis — 3 patches; 12 hours in 24); capsaicin 0.075% cream 3–4×/day. High-strength capsaicin 8% patch (Qutenza): specialist clinic application; highly effective for PHN. Document dermatomal distribution; confirm prior shingles episode.
Scenario C — Trigeminal neuralgia Unilateral facial pain; lancinating; seconds duration; triggered by touch; eating; talking; cold. NEVER at night (unlike other neuropathic pain). First-line: carbamazepine 100mg BD → titrate to 400–1200mg/day. Monitor: Na+ (SIADH; hyponatraemia); FBC (agranulocytosis); LFTs; drug interactions (CYP450 inducer). If intolerable: oxcarbazepine 150mg BD. Neurology referral if: diagnosis uncertain; refractory; surgical candidacy (MVD). Key SCA point: carbamazepine for TN — NOT amitriptyline or gabapentin as first-line.
Scenario D — Central neuropathic pain (MS or post-stroke) Neuropathic pain in the context of MS or stroke: burning; dysaesthesia; allodynia; often bilateral; associated with upper motor neurone signs. Management: amitriptyline; gabapentin; pregabalin — same agents as peripheral, often requiring specialist input. NICE CG173 recommends the same drugs but notes that central neuropathic pain often requires specialist involvement (neurology; pain clinic). Key point: pain in MS may also be due to spasticity (baclofen; tizanidine) or trigeminal neuralgia (carbamazepine).
Scenario E — Neuropathic pain with renal impairment Patient with eGFR 32: first-line gabapentinoid dose must be reduced (approximately 50% of standard dose for eGFR 30–59). Amitriptyline or duloxetine (avoid duloxetine if eGFR <30) may be preferred. Key check before any gabapentinoid: U&E and eGFR. Prescribing standard-dose pregabalin with eGFR 32 = clinical error. Calculate dose reduction: gabapentin maximum 900mg/day at eGFR 30–59. Pregabalin: reduce proportionally. Document renal function at time of prescribing.
Key variables to adapt for Underlying cause (diabetic neuropathy vs PHN vs TN vs central — each has different first-line choices); comorbid depression (PHQ-9 ≥10: prefer duloxetine); renal function (eGFR <60: adjust gabapentinoid dose; eGFR <30: avoid duloxetine); cardiovascular risk (amitriptyline: QTc; caution in cardiac history); medication tolerance; age (elderly: start low; go slow; fall risk from sedation); topical options for PHN (lidocaine patches; capsaicin); prior treatment response; pain severity and functional impact (DN4 score; BPI)
Steps:
1
Step 1
History — Pain Character · DN4 · Cause Identification · PHQ-9 · ICE · Yellow Flags
collapse
The history in neuropathic pain is the diagnosis: no test confirms the mechanism. Pain quality (burning; shooting; electric shock; allodynia); distribution (dermatomal or nerve territory); temporal pattern (worse at night); underlying cause (DM; shingles; MS); and prior treatment response (failure of NSAIDs and paracetamol is a diagnostic clue) together establish the neuropathic mechanism. The DN4 questionnaire structures this assessment.
🎓 SCA opener — acknowledge the emotional impact before the symptom checklist
"I can see this has been really wearing you down. Six months of pain stopping you sleeping and stopping your daily walks — that takes a real toll. Before I ask specific questions, tell me in your own words what this pain has been like."
Mrs. Osei is tearful. A GP who begins with a clinical checklist will get a closed history. One who acknowledges the emotional cost first gets an open narrative including the amputation fear she is too frightened to raise directly.
1A — Open question, then DN4-structured pain characterisation
QuestionWhy it mattersChanges what?
🏲 OPEN QUESTION"Tell me in your own words what the pain has been like — what it feels like, where it is, how it has been affecting you."The open question reveals: pain quality (burning; shooting; electric shocks — the vocabulary of neuropathic pain); distribution; temporal pattern (night worsening); functional impact; and the emotional dimension. The key distinction: neuropathic descriptors (burning; electric shock; pins and needles) vs nociceptive (aching; throbbing) immediately guides diagnosis and treatment class. It also reveals the patient’s illness model — often "my diabetes must be getting much worse."SCA: Global Skills; yellow flags; ICE emerging from narrativeNeuropathic descriptors; distribution; temporal pattern; emotional dimension; hidden agenda
Pain quality — neuropathic vocabulary (DN4)"Does it feel burning? Like electric shocks? Pins and needles? Is the skin sensitive to touch — even a bedsheet or clothing?"The DN4 questionnaire systematically captures neuropathic pain descriptors: burning; painful cold; electric shocks; tingling; pins and needles; numbness; itching; hypoaesthesia to touch; hypoaesthesia to prick; allodynia to brushing. Mrs. Osei: burning “like hot coals”; electric shock; pins and needles — likely DN4 ≥4/10. This explains why NSAIDs (targeting prostaglandin-mediated nociception) do not work for nerve pain.≥4 DN4 items: neuropathic mechanism; NICE CG173 first-line drugs. <4: reassess mechanism; may need NSAIDs for nociceptive component
Distribution and laterality"Where exactly? Is it both feet? Does it go up your legs? Any pattern?"Distribution identifies the cause. Bilateral symmetrical stocking: DPN; B12 deficiency; alcohol. Unilateral dermatomal: post-herpetic neuralgia; radiculopathy. Facial trigger-activated: trigeminal neuralgia. Bilateral ascending: inflammatory neuropathy — neurology. Mrs. Osei: bilateral feet — length-dependent DPN (longest nerves affected first).Bilateral stocking: DPN; B12; alcohol. Unilateral dermatomal: PHN. Facial: TN → carbamazepine. Ascending/atypical: neurology
Temporal pattern"Is it worse at night? Does anything make it better or worse? Does movement help or worsen?"Night worsening: characteristic of DPN and PHN (peripheral blood flow reduction; no distracting stimuli). Trigeminal neuralgia: NOT at night (distinguishes it from other neuropathic conditions). Night worsening also explains why amitriptyline at night is particularly useful — sedative effect at bedtime; analgesic benefit overnight.Night-worsening: DPN; PHN → amitriptyline at night particularly useful. Trigger-activated seconds: TN → carbamazepine. NOT at night: TN
Prior treatment response"What have you tried? Has any of it helped? Have you been prescribed anything specifically for nerve pain?"Failure of paracetamol and NSAIDs for 3 months is a key diagnostic clue. NSAIDs/paracetamol treat prostaglandin-mediated nociceptive pain — they do not work on ectopic discharge from damaged nerve fibres. This failure directly justifies switching drug class and frames the consultation: Mrs. Osei needs a different mechanism of drug, not a stronger painkiller. This also prevents the common error of prescribing opioids (codeine; tramadol) as the next escalation step.NSAID + paracetamol failure: confirms neuropathic mechanism; switch to NICE CG173 first-line. Do NOT escalate the analgesic ladder — switch class
1B — Red flags requiring urgent investigation
🚨

Red Flags — neuropathic pain presentations requiring urgent action

Red flagConcernAction
Cauda equina features — saddle numbness + bladder/bowelCord compression causing neuropathic pain as presenting feature. Any perianal or perineal neuropathic pain + bladder/bowel change: 999. Emergency MRI.999 / same-day A&E — emergency MRI
Rapidly ascending weakness + sensory loss (GBS pattern)Guillain-Barré syndrome: ascending weakness + sensory loss; ascending from feet; neuropathic pain as precursor; respiratory failure risk. Medical emergency.999 — hospital admission; respiratory monitoring; IVIG
Neuropathic pain in known cancer patient + new back painSpinal cord or nerve root compression from metastases. Urgent MRI full spine. Dexamethasone 8mg if cord compression suspected.Same-day urgent MRI; dexamethasone; oncology
Shingles (VZV rash) — within 72 hours of onsetAntiviral treatment (aciclovir or valaciclovir) within 72 hours of rash reduces severity and PHN risk. After 72 hours: antivirals less effective but may still help if new lesions forming.Antiviral within 72h; adequate analgesia; ophthalmology if eye involvement
Rapidly progressive or asymmetric neuropathyVasculitis; CIDP; sarcoidosis; malignancy-associated. Multiple nerve territories; constitutional features. Urgent neurology.Urgent neurology — NCS; vasculitis screen; ANCA; ESR
🛡️

Safeguarding — Chronic Pain, Depression, and Vulnerability in Mrs. Osei

PHQ-9 12 (moderate depression) + chronic pain + sleep deprivation in a 67-year-old woman = significant vulnerability. Suicidality screening is mandatory. Medication overdose risk (amitriptyline has low therapeutic index in overdose). Social isolation from inability to walk. Financial exploitation risk.
💕 Suicidality — PHQ-9 Q9
  • PHQ-9 Q9 specifically: ask about suicidal ideation at this consultation and at 2-week review after antidepressant initiation
  • If Q9 ≥1: urgent mental health assessment regardless of total score
  • Amitriptyline: low therapeutic index — if any suicidality concern: supply restrict to 2-week prescriptions; prefer duloxetine (slightly safer in overdose)
  • All antidepressants: increased suicidal ideation risk in first 4 weeks — document safety-net given
🏠 Social isolation and elder vulnerability
  • Unable to walk — main social activity lost; progressive isolation; depression worsening
  • Ask: who does she live with? Social support? Community activities?
  • Social prescribing: pain support groups; befriending services; adapted exercise
  • Elder financial abuse: chronic illness increases vulnerability; if any concern about finances or home situation: social services referral
📈 Diabetes self-management
  • Depression reduces diabetes self-management (medication adherence; dietary control; exercise)
  • PHQ-9 ≥10 independently predicts poor diabetes outcomes — treating depression is treating diabetes
  • Poor sleep from pain → raised cortisol → worsened glucose control → worse neuropathy — a vicious cycle
  • Refer to diabetes nurse specialist for holistic support
💋 Medication safety
  • Gabapentinoids: Schedule 3 CD; misuse potential; sedation increases fall risk in elderly
  • Amitriptyline: dangerous in overdose (QRS widening; arrhythmia); prescribe 2-week supply if depression + suicidality concern
  • Do not prescribe strong opioids for neuropathic pain in an elderly patient with depression — addiction and overdose risk
Actions: PHQ-9 Q9 specifically checked; suicidality safety-net given for antidepressant initiation documented; if amitriptyline chosen with PHQ-9 ≥10: 2-week supply only; social prescribing referral; diabetes nurse referral; NHS Talking Therapies referral.
1C — PMH · Drug history · Social history
🥐 PMH · Comorbidities
FactorWhy it mattersImpact
DM ×12 years; HbA1c 62DPN correlates with diabetes duration and HbA1c. HbA1c optimisation is disease-modifying. DCCT/UKPDS: intensive control reduces DPN risk by 60%. Referral to diabetes team for HbA1c optimisation is part of DPN management.Diabetes team referral; SGLT2 inhibitor or GLP-1 RA consideration; annual foot check
Cardiac history; ECG and QTcAmitriptyline prolongs QTc — check ECG in cardiac-risk patients before prescribing. QTc >450ms (women): avoid amitriptyline; prefer duloxetine or gabapentinoid. Mrs. Osei: age 67 + DM = cardiovascular risk; check ECG.ECG before amitriptyline in cardiac-risk patients. QTc >450ms: avoid TCA
Renal function (eGFR)DM ×12 years = nephropathy risk. eGFR MUST be checked before gabapentinoids (renally excreted; dose-adjust at eGFR <60). Duloxetine: avoid if eGFR <30. Amitriptyline: no dose adjustment in mild-moderate renal impairment.Check eGFR before all prescriptions. eGFR <60: reduce gabapentinoid dose. eGFR <30: avoid duloxetine; prefer amitriptyline
B12 and TFTsMetformin reduces B12 absorption. B12 deficiency causes peripheral neuropathy that coexists with or mimics DPN. Hypothyroidism also causes neuropathy. Both are treatable and should be excluded.Check B12; TFTs. B12 <150: replace (IM hydroxocobalamin). Hypothyroid: thyroid replacement may reverse neuropathy
💊 Drug history · Social history
FactorWhy it mattersImpact
Current: metformin; sitagliptin; paracetamol; ibuprofenIbuprofen ineffective for neuropathic pain AND has nephropathy risk in DM. Must stop. Paracetamol may continue as adjunct for mixed pain. Metformin: B12 depletion (check). No significant drug interactions with duloxetine or amitriptyline.Stop ibuprofen (today). Review paracetamol. Start NICE CG173 first-line. B12 with metformin check
Alcohol intakeAlcohol causes peripheral neuropathy and worsens DPN. Increases CNS depression risk combined with amitriptyline or gabapentinoids. Worsens sleep and depression. Ask routinely.Significant alcohol: AUDIT-C; alcohol-related neuropathy; thiamine; B12; caution combining with sedating analgesics
Social support; isolationMrs. Osei has lost her daily walk (main social activity). Ask: who does she live with? What activities has she stopped? Social isolation worsens depression and pain. Social prescribing: pain groups; adapted exercise; befriending.Social prescribing referral; NHS Talking Therapies; adapted exercise; community pain groups
DrivingAmitriptyline; gabapentinoids: sedation — DVLA: must not drive if impaired. Duloxetine: less sedating but warn about initial period. Document driving advice.Warn: no driving until medication established; document advice given
1D — ICE
💡 Ideas
"What do you think is causing this pain? What is your understanding of what is happening with your diabetes?"
Mrs. Osei believes her diabetes is “getting a lot worse.” She may have a specific unvoiced fear — amputation (her friend had one). Correcting the catastrophic illness model (“this means amputation”) is as therapeutically important as prescribing the correct drug.
😟 Concerns
"What worries you most? Is there something specific you are frightened might happen?"
Amputation fear: must be raised directly if not volunteered. “DPN does not mean you are going to lose your feet. Amputation in diabetes occurs from infected foot ulcers — not from neuropathic pain alone. Your feet have no ulcers right now.” The GP who does not address this leaves the most frightening thing unresolved.
🎯 Expectations
"What were you hoping today would give you? Something to take the pain away completely?"
Setting expectations: “I cannot promise the pain will go away completely. We aim for a 30–50% reduction. If you are at 8/10 now, the target is 4/10. Most patients find that level of improvement makes an enormous difference to their sleep and quality of life.” Honest, specific expectations prevent premature discontinuation.
1E — Psychosocial context
🧑️ Chronic neuropathic pain is a biopsychosocial condition — psychological and social dimensions determine long-term outcome

Mrs. Osei’s pain sits within chronic disease anxiety; comorbid depression (PHQ-9 12); sleep disruption; functional limitation; social isolation; and self-blame for imperfect diabetes control. Each amplifies pain through central sensitisation. Treatment addressing only the pharmacological component will produce a partial response.

📈 Fear of DM Progression

Mrs. Osei interprets her pain as evidence that diabetes is “getting worse.” This catastrophic belief amplifies pain through central sensitisation. Must be directly addressed: DPN is caused by long-term hyperglycaemia; the pain is the nerve’s response; HbA1c optimisation prevents further damage; pain does not mean imminent amputation.

"The pain in your feet is a complication of diabetes — it means the nerves are irritated by years of raised blood sugar. This doesn’t mean your diabetes is out of control — it means we need to manage it better and treat the nerve pain directly."
💔 Amputation Fear

Mrs. Osei’s friend had a diabetic amputation. This is a powerful fear she is likely carrying. Amputation occurs from infected foot ulceration — not from neuropathic pain per se. Naming this fear, correcting it with accurate information, and offering podiatry referral as active prevention is both reassuring and clinically appropriate.

"I want to address what I think may be worrying you. Amputations in diabetes happen when there is a wound that doesn’t heal — because of poor circulation. You don’t have that right now. The podiatrist will help us keep a close eye on your feet."
😴 Sleep and Pain Cycle

Night pain → poor sleep → reduced endogenous pain inhibition → more pain. Amitriptyline at night addresses both pain and sleep. If duloxetine chosen (morning dosing; may cause insomnia): add low-dose amitriptyline 10mg at night for sleep benefit if needed.

"Has the pain been waking you up? Poor sleep and pain have a difficult relationship — they make each other worse. One reason I am choosing this particular medication is that it also helps with sleep when taken at night."
💓 Loss of Identity and Activity

Daily walking was Mrs. Osei’s primary physical and social activity. Its loss worsens depression, isolation, and pain. Adapted exercise (swimming; chair yoga; short walks to tolerance) replaces what can be replaced. Exercise is both analgesic and antidepressant.

"I know not being able to walk has taken a lot from you — not just the physical health but everything that came with it. Let’s see if we can get you to some adapted exercise while the treatment gets to work."
🎓 SCA Checkpoint — Step 1TasksRelating to OthersGlobal Skills
Key phrases that score
"I can see this has been really wearing you down. Before I ask specific questions — tell me in your own words what this pain has been like."
"The type of pain you are describing — burning; electric shocks; worse at night — sounds very much like nerve pain. That is important because it means the paracetamol and ibuprofen are not going to work for this type of pain. They treat tissue damage pain — not nerve pain. Nerve pain needs a completely different drug."
"I want to ask something directly — are you frightened about losing your feet? I ask because I want to address that worry specifically."
Deductions
  • Prescribing stronger opioids without explaining why current drugs fail — opioids are not first-line for neuropathic pain and miss the mechanism
  • Not acknowledging Mrs. Osei’s distress before clinical questions
  • Not addressing the amputation fear if it emerges
🔴 Red
No acknowledgement of distress; opioids prescribed; NSAIDs continued; why NSAIDs fail not explained; PHQ-9 not administered; depression not addressed; amputation fear unaddressed; no podiatry
🟠 Amber
Distress acknowledged; DPN diagnosed; correct drug prescribed; why NSAIDs fail not explained; PHQ-9 scored; treatment expectations not set; amputation fear not raised; 4-week review not booked
🟩 Green
Emotional opener; DN4 elicited; DPN mechanism explained; why NSAIDs fail explained; duloxetine (dual indication); PHQ-9 12 + suicidality; amputation fear raised + addressed; 30–50% expectation; HbA1c + diabetes team; podiatry; 4-week review; suicidality safety-net; driving advice
2
Step 2
Triage — Emergency · Urgent · GP-Managed Neuropathic Pain
collapse
Most neuropathic pain is GP-managed. The triage question is: emergency (cord compression; GBS); urgent referral (rapidly progressive; vasculitis; shingles within 72h); or GP-managed (DPN; PHN; TN)?
🔴 Emergency

999 / Same-Day Hospital

Immediate
  • Cauda equina syndromeSaddle numbness + bladder/bowel; 999; emergency MRI
  • Guillain-Barré syndromeAscending weakness; respiratory risk; 999; IVIG
  • Cord compression — cancer patient + back painSame-day; dexamethasone; urgent MRI
🟠 Urgent

Urgent Referral

Days to 2 weeks
  • Shingles — within 72h of rashAntiviral (aciclovir/valaciclovir); ophthalmology if eye
  • Rapidly progressive or atypical neuropathyNeurology; NCS; vasculitis screen; ANCA
🟩 GP-managed — Mrs. Osei

Primary Care

NICE CG173
  • Diabetic peripheral neuropathy — Mrs. OseiDuloxetine first; HbA1c optimisation; podiatry
  • Post-herpetic neuralgiaAmitriptyline; gabapentinoid; lidocaine patches
  • Trigeminal neuralgiaCarbamazepine; neurology if refractory
🎓 SCA Checkpoint — Step 2Tasks
Reassurance
"The pattern of pain you have — bilateral; burning; worse at night; with 12 years of diabetes — is a recognisable pattern called diabetic peripheral neuropathy. There are no emergency features. The pain is not spreading rapidly upwards and there are no bladder or bowel problems. This is something we manage in primary care."
Deductions
  • Not screening for cauda equina features in a patient with lower limb neuropathic pain
3
Step 3
Examination — Monofilament · Vibration · Reflexes · Foot Inspection
collapse
The examination confirms the clinical picture and identifies severity and foot ulceration risk. The monofilament test is the most important clinical examination in DPN.
ExaminationWhat it showsManagement impactChanges?
10g monofilament (Semmes-Weinstein)10 sites per foot; loss of sensation at ≥1 site = protective sensation lossProtective sensation loss = risk of unnoticed foot injury → ulceration → infection → amputation. This is the key examination for diabetic foot risk stratification. Must be performed and documented. Informs podiatry referral urgency and foot care education.Sensation loss: urgent podiatry; foot care education; high risk. Sensation intact: standard podiatry; standard review.YES — determines ulceration risk; podiatry referral urgency
Vibration sense (128Hz tuning fork; great toe)Vibration (large fibre) is typically first impaired in DPN. Loss at great toe: early DPN. Loss up to knee: more severe. Baseline for comparison at future reviews.Loss at great toe: DPN confirmed; standard management. Loss to knee: more severe; urgent HbA1c optimisation; consider neurology if atypical.YES — severity assessment; baseline
Ankle reflexes; knee reflexesAnkle jerk: first reflex lost in DPNAbsent ankle jerks (bilateral) = distal DPN. Hyperreflexia + neuropathic pain: cord compression or MS — specialist review.Bilateral absent ankle jerks: distal DPN; standard management. Hyperreflexia: cord compression; neurology urgently.YES — asymmetric or UMN signs = urgent referral
Foot inspection — all surfaces; ulcers; callus; pulsesAn active foot ulcer is a medical emergency in diabetes — must be excluded before sending home with outpatient plan. Inspect all surfaces (including between toes and under heels). Check dorsalis pedis + posterior tibial pulses (absent = peripheral arterial disease).Active ulcer: same-day emergency podiatry; wound culture; antibiotics; offloading; vascular. No ulcer: standard DPN management + foot care education.YES — active ulcer changes urgency completely
🎓 SCA Checkpoint — Step 3Tasks
Foot examination
"I am going to check the sensation in your feet with a small filament — this tests whether the protective nerve endings are working. If the protective sensation is reduced, you can injure your foot without feeling it. I will also look closely at your feet."
Deductions
  • Not inspecting the feet in a diabetic patient with foot neuropathic pain — an active ulcer must be excluded before an outpatient plan; missed diabetic foot ulcer is a significant patient safety event
4
Step 4
Investigations — eGFR Before Prescribing · DN4 · PHQ-9 · ECG · HbA1c · B12
collapse
Investigations serve two purposes: confirming the underlying cause; and establishing safety parameters before first-line prescribing. Critical pre-prescribing checks: eGFR (before gabapentinoids); ECG (amitriptyline in cardiac-risk patients); LFTs + BP (duloxetine); PHQ-9 (mandatory).
InvestigationClinical questionResult and action
DN4 questionnaire (10 items)Complete at first appointment; document scoreFormally structures neuropathic pain diagnosis. Score ≥4/10: neuropathic mechanism confirmed; NICE CG173 first-line drugs appropriate. Re-score at 4-week review: ≥2-point improvement = clinically meaningful response.≥4/10: neuropathic confirmed; first-line drugs. <4: mixed or nociceptive — reconsider mechanism.
PHQ-9 (and Q9 specifically)Mandatory at first appointment and every reviewDepression co-exists in 30–60% of chronic neuropathic pain. Mrs. Osei: score 12 = moderate depression. PHQ-9 Q9: suicidal ideation — must ask and document. Score ≥1 on Q9: urgent mental health referral. Also informs drug choice: PHQ-9 ≥10 + DPN = duloxetine (dual indication).PHQ-9 <10: watchful waiting. 10–19: duloxetine (dual); NHS Talking Therapies; risk assess. Q9 ≥1: urgent mental health; supply restrict amitriptyline.
U&E + eGFR — mandatory before gabapentinoidsAlso metformin review; duloxetine safetyGabapentin and pregabalin are renally excreted: dose-adjust at eGFR <60. Mrs. Osei: DM ×12 years = nephropathy risk. Duloxetine: avoid if eGFR <30. Prescribing standard-dose gabapentinoid with eGFR 35 = prescribing error. Check K+ and Na+ if using carbamazepine.eGFR >60: standard gabapentinoid dose. eGFR 30–59: 50% dose. eGFR <30: specialist; avoid duloxetine; amitriptyline preferred. Metformin: stop if eGFR <30.
HbA1c; ECG; B12; LFTsPre-prescribing safety; disease-modifying checkHbA1c: disease-modifying; referral to diabetes team if above target. ECG: QTc check before amitriptyline in cardiac-risk patient (age 67; DM). B12: metformin depletes B12; deficiency mimics DPN; check and replace if low. LFTs before duloxetine (avoid in severe hepatic impairment; NICE).HbA1c >53: diabetes team referral; SGLT2i. ECG QTc >450ms (F): avoid amitriptyline. B12 <150: replace. LFTs abnormal: review duloxetine choice.
🎓 SCA Checkpoint — Step 4Tasks
Investigations communication
"I want to check a couple of things before prescribing. The main one is your kidney function — because some of the medications need to be adjusted depending on that. I also want to check your B12, because the metformin you take can occasionally reduce B12 absorption and B12 deficiency itself causes nerve pain. And an ECG as a safety check before the medication."
Deductions
  • Prescribing gabapentin or pregabalin without checking eGFR first — mandatory; prescribing standard dose with eGFR <60 = prescribing error
5
Step 5
Diagnosis — Plain Language · Why NSAIDs Fail · DPN Classification · Treatment Expectations
collapse
The diagnosis must be shared in plain language that explains the mechanism, corrects the amputation illness model, sets honest treatment expectations, and explains why the previous drugs failed. Each of these elements is independently tested in the SCA.
🗣️ Explaining diabetic neuropathy — plain language for Mrs. Osei

"Your pain is coming from the nerves in your feet. When blood sugar is slightly high over many years, it gradually damages the fine nerve endings. When nerves are damaged, they become irritated and send pain signals even when nothing is actually hurting the foot — like a fire alarm that keeps going off when there is no fire. That is why you feel burning; shooting pain; electric shocks — these are the damaged nerves misfiring. This is called diabetic peripheral neuropathy. It is a recognised complication of diabetes and it is treatable — though I want to be honest: we aim for a significant improvement, not necessarily complete elimination of the pain. The reason paracetamol and ibuprofen have not helped is that they treat a completely different kind of pain — tissue damage and inflammation. Your pain is not from tissue damage; it is from irritated nerves firing abnormally. The drugs that work for nerve pain are completely different."

💬 Addressing the core concerns

"Does this mean I am going to lose my feet?"
"I want to address that directly, because I think it may be worrying you. Amputations in diabetes happen when there is a wound or injury to the foot that doesn’t heal — usually because of poor circulation and infection. The nerve pain you have is different: it is a sign that the nerves are irritated, not that you are about to lose your feet. You don’t have any foot wounds right now — and the most important thing we can do together to prevent problems is to make sure your feet are looked after properly. I am referring you to the podiatrist today."

"Why haven’t my painkillers worked?"
"Paracetamol and ibuprofen work by reducing inflammation and blocking the chemical signals of normal tissue damage pain. But your pain is not from tissue damage — it is from nerves misfiring. These drugs act on completely the wrong pathway. The tablets I am going to prescribe today work specifically on the nerve pain pathways — in the spinal cord — where they can quiet down the misfiring signals."

Setting treatment expectations
"I want to be honest with you about what the medication can achieve. We aim for a reduction of at least 30 to 50 percent in your pain. If you are at 8 out of 10 now, the target is 4 out of 10. I know that doesn’t sound like complete relief — but most patients find that level of improvement makes an enormous difference to their sleep; their ability to walk; their mood; their quality of life. The tablets take 4 to 8 weeks to work at the right dose. Please do not stop them at 2 weeks if you still have some pain."

Mrs. Osei’s Diagnosis: DPN
GP diagnosis; NICE CG173
Bilateral burning feet; DN4 ≥4; worse at night; DM ×12y; HbA1c 62; monofilament loss; stocking distribution; NSAIDs + paracetamol failed. PHQ-9 12 (moderate depression). First-line: duloxetine 30mg OD → 60mg OD (dual indication: DPN + depression).
Exclude or Consider
Check if atypical

B12 deficiency neuropathy

Metformin-related. Check B12; replace if <150 pg/mL. Can coexist with DPN.

Hypothyroid neuropathy

Check TFTs; treatment may reverse neuropathy.

Emergency Exclusions
Documented as absent

Active foot ulcer

Foot inspection: no active ulcer documented today. Podiatry referral made.

Cauda equina; GBS

Not present: no bladder/bowel change; no ascending weakness. Documented.

📊 Neuropathic pain classification — cause determines first-line treatment
CausePatternFirst-lineSpecial treatment
Diabetic peripheral neuropathyBilateral stocking; burning; worse at night; DM historyAmitriptyline; duloxetine; gabapentin; pregabalin (NICE CG173) — duloxetine if PHQ-9 ≥10HbA1c optimisation (disease-modifying); podiatry; foot care; annual foot check
Post-herpetic neuralgia (PHN)Unilateral dermatomal; follows shingles; allodynia; burningAmitriptyline; gabapentin; pregabalinTopical: lidocaine 5% patches (Versatis; 3 patches 12h on/12h off); capsaicin 0.075% cream; Qutenza (specialist)
Trigeminal neuralgiaUnilateral facial; lancinating; seconds; triggered by touch; NOT at nightCarbamazepine 100mg BD → titrate (NOT amitriptyline/gabapentin first-line)Monitor Na+ (SIADH); FBC; LFTs; CYP450 interactions; neurology if refractory; MVD surgery
Central neuropathic pain (MS; stroke)With neurological disease; dysaesthesia; may be bilateral; allodyniaAmitriptyline; gabapentin; pregabalin — often requires specialist inputNeurology specialist; MS spasticity: baclofen; tizanidine (separate from neuropathic pain)
🎓 SCA Checkpoint — Step 5TasksRelating to Others
The critical communication
"I want to be honest with you about what this medication can achieve. We aim for a significant improvement — not necessarily complete elimination of the pain, but a reduction of 30 to 50 percent. If you are at 8 out of 10 now, the target is 4 out of 10. Most people find that improvement makes an enormous difference to their sleep and their quality of life. And I am choosing this particular medication because it also helps with the low mood you have been experiencing."
Deductions
  • Not setting treatment expectations (30–50% reduction; 4–8 weeks) — the patient who is not told this will stop the medication at 2 weeks if they still have some pain
  • Not correcting the amputation illness model when it emerges
6
Step 6
Referral — Podiatry · Diabetes Team · Pain Clinic · Neurology
collapse
DPN management requires multi-professional input: GP for pharmacology; podiatry for foot protection; diabetes team for HbA1c optimisation; pain clinic if primary care management fails.
ReferralUrgencyGP actionsMust NOT do
Podiatry — foot protection serviceRoutine — 2–4 weeks; same-day if active ulcerRefer to NHS foot protection / podiatry service. Include: DM ×12y; DPN; monofilament result; foot inspection result. Podiatry will: assess foot risk category; provide foot care education; manage callus and nails; provide insoles. Interim today: teach Mrs. Osei to inspect feet daily (mirror for soles); wear well-fitting cushioned shoes; never walk barefoot; report any redness; wound; blister immediately.Do NOT defer foot care education to the podiatrist — give basic advice today. Do NOT miss an active ulcer — this changes urgency to same-day emergency referral.
Diabetes team / DSN — HbA1c optimisationRoutine — 4–6 weeksMrs. Osei HbA1c 62 (target <53 on oral agents): refer to diabetes specialist nurse or diabetologist. Consider SGLT2 inhibitor (empagliflozin; dapagliflozin — also cardiovascular + renal protection) or GLP-1 RA (liraglutide; semaglutide). DCCT/UKPDS: intensive glucose control reduces DPN progression. HbA1c optimisation is disease-modifying for DPN — not just diabetes management.Do NOT treat DPN in isolation from diabetes. HbA1c optimisation is part of DPN management. Do NOT prescribe insulin without diabetologist involvement.
NHS Talking Therapies — depression + chronic painRoutine — self-referral or GP referralPHQ-9 12 = moderate depression. NHS Talking Therapies referral: CBT + neuropathic pain management gives better outcomes than pharmacology alone. CBT addresses catastrophising; fear avoidance; functional limitation; sleep disruption. Online programmes: SilverCloud; Beating the Blues. Pain management programme if NHS Talking Therapies inadequate. Duloxetine addresses both depression and pain pharmacologically; NHS Talking Therapies addresses psychological dimension.Do NOT treat depression and pain as separate problems — they are interrelated. Do NOT rely solely on medication without psychological support.
Pain Management Programme / Pain ClinicRoutine — after two failed first-line agentsNICE CG173: refer if two first-line agents tried at adequate dose for adequate duration have failed; or diagnosis uncertain; or complex psychological comorbidity. Specialist options: high-dose pregabalin/gabapentin; lidocaine infusions; ketamine; spinal cord stimulation for DPN (NICE IPG450). For Mrs. Osei: not yet indicated — first-line drug not yet tried. Plan if duloxetine + second agent both fail at 8 weeks.Do NOT refer before trying two adequately dosed first-line agents. Do NOT use pain clinic as an exit before proper primary care management.
🎓 SCA Checkpoint — Step 6Tasks
Referral communication
"I am going to refer you to the podiatrist — they are specialists in foot care for diabetes and they will keep a close eye on your feet and advise on how to protect them. I am also asking the diabetes nurse to see you about your blood sugar levels — because improving your control will help prevent the nerve pain getting any worse."
Deductions
  • Not referring to podiatry in a diabetic patient with neuropathy and possible protective sensation loss — NICE quality standard; significant clinical omission
7
Step 7
Management — Duloxetine First-Line · Drug Titration · Stop NSAIDs · Foot Care · HbA1c · Safety-Netting
collapse
7A — Address the core expectation: “I need something that actually works”
🤝
Mrs. Osei has been taking the wrong drug class for 3 months — validate the frustration; explain the mechanism; offer a credible plan with a specific timeline
1
Validate — the frustration is earned

Three months of pain; three months of ineffective tablets; three months of lost sleep. The frustration is rational.

"I completely understand the frustration — you have been taking tablets every day for 3 months that haven’t helped. And I want to explain why they haven’t worked, and what we are going to do differently — because there are drugs that do work for this type of pain."
2
Explain the mechanism difference specifically

A patient who understands why the new drug is different will persist through the titration period. One who simply receives a new prescription without explanation will stop it at 2 weeks.

"Paracetamol and ibuprofen work on inflammation and prostaglandins — the chemical signals of tissue damage pain. But your pain is coming from damaged nerves that are misfiring — not from tissue damage. The new tablet works on the nerve pain pathways in your spinal cord — it is a completely different mechanism. That is why I am not prescribing a stronger version of what you have been taking."
3
Set honest expectations — 30–50% reduction; 4–8 weeks

The patient who is promised complete pain relief will be disappointed. The patient who is promised significant improvement with a realistic timeframe will be better equipped to persist.

"This drug takes 4 to 8 weeks to work at the right dose. The target is to get your pain from 8 out of 10 down to 4 out of 10. I know that’s not complete relief — but most people find that level of improvement makes an enormous difference to their sleep; their ability to walk; their mood. I will review you in 4 weeks to see how it is going."
Key principle: The patient who understands they are on a 4–8 week trial of a drug that works by a different mechanism — and who has been given a specific review date — is far more likely to persist than one who simply receives a prescription with no context.
7B — Treatment goals
Treatment goals for Mrs. Osei
30–50% pain reduction from baseline (NRS and DN4 tracked)Sleep improvement — sleeping through with fewer pain awakenings Return to walking (adapted as needed) — short walks building to dailyPHQ-9 improvement — target <10 at 8 weeks HbA1c towards target (<53 mmol/mol) via diabetes teamNo foot ulcers — podiatry monitoring; daily foot inspection 4-week review booked; titration plan explained; escalation clearMrs. Osei understands the neuropathic mechanism; why NSAIDs fail; what duloxetine does; when to expect benefit
Motivational framing
"You have had 3 months of taking the wrong type of tablet for this pain. That has been frustrating and it has not been your fault — neuropathic pain is easily mistaken for normal pain. But now we know what it is, we can use the right treatment."
"I am choosing this particular medication because it helps with both the pain and the low mood you have been experiencing. The two things are connected — pain drives low mood; low mood amplifies pain. One medication addressing both is genuinely better than two separate prescriptions."
7C — Non-medication management
🙎
Foot Care Education
Daily inspection; well-fitting shoes; never barefoot; report any wound immediately
Why critical

Protective sensation loss means Mrs. Osei may not feel a foot injury. A small wound that goes unnoticed can become a large ulcer, then infected, then a potential amputation trigger. Daily foot inspection is the single most effective intervention for preventing diabetic foot complications — and teaching it today is as important as the prescription.

Practical

Inspect both feet daily with a mirror for the soles. Check between toes. Report any redness; wound; blister; or colour change immediately. Well-fitting cushioned shoes at all times. Never walk barefoot. Moisturise dry skin (not between toes). No home corn or callus treatment — podiatrist only.

Daily inspection: most effective prevention of diabetic foot complications; teach today before podiatry appointment
🏃
Adapted Exercise
Short walks to tolerance; chair exercise; swimming; build up as pain allows
Evidence

Exercise is analgesic (endorphins; descending inhibitory activation); improves HbA1c; reduces depression. Mrs. Osei has stopped her daily walks — this worsens both pain and depression. Adapted exercise preserves function and breaks the deconditioning cycle. Social prescribing: exercise on prescription; chronic pain exercise groups.

Practical

Short walks (5–10 min); increase as pain allows. Swimming: excellent (unloads feet; aerobic; social). Chair-based yoga or stretching. Exercise on prescription referral. Goal: “Can you walk to the end of the road and back this week?”

Adapted exercise: analgesic; HbA1c improvement; mood; social connection
🧠
CBT and NHS Talking Therapies
NHS Talking Therapies referral; CBT for chronic pain + depression; pain management programme if needed
Evidence

CBT + pharmacological treatment is more effective than pharmacology alone for chronic neuropathic pain with comorbid depression. Acceptance and Commitment Therapy (ACT): values-based living despite pain — particularly effective. NHS Talking Therapies: Low or High Intensity CBT depending on PHQ-9 severity.

Practical

NHS Talking Therapies self-referral or GP referral. Online CBT (SilverCloud; Beating the Blues). Pain management programme referral if NHS Talking Therapies inadequate. Set expectation: CBT takes 6–12 weeks; works best alongside medication.

CBT + drug treatment: more effective than drugs alone; addresses catastrophising; fear avoidance; functional limitation
Sleep Hygiene
Consistent sleep schedule; avoid caffeine after 2pm; amitriptyline at night for combined benefit
Why it matters

Night pain → sleep disruption → reduced endogenous pain inhibition → more pain. Treating sleep is a pain intervention. Amitriptyline at night addresses both. If duloxetine chosen (morning dosing; may cause insomnia): add low-dose amitriptyline 10mg at night for sleep if needed.

Practical

Regular sleep/wake times. Avoid caffeine after 2pm. Cool; dark bedroom. No screens before bed. Progressive muscle relaxation. Sleep restriction therapy if chronic insomnia. Duloxetine in the morning; amitriptyline at 10pm if used.

Improving sleep reduces central sensitisation; improves mood; reduces pain perception
📓
Patient Education
Diabetes UK; Pain Concern; NHS chronic pain resources; foot care leaflet today
Why

Patients who understand their condition — the mechanism; the rationale for treatment; the timeline; self-management — have better outcomes. Mrs. Osei needs to understand: why NSAIDs fail; what duloxetine does; when to expect benefit; foot care; when to seek help urgently.

Resources

Diabetes UK foot care guide (diabetes.org.uk). Pain Concern helpline: 0300 123 0789. NHS chronic pain leaflet. Living Well with Persistent Pain: persistent-pain.readingwell.org.uk. NHS Talking Therapies leaflet + self-referral if PHQ-9 ≥10.

Education improves medication adherence; self-management; early foot problem reporting
👐
HbA1c Optimisation
Diabetes team referral; SGLT2i or GLP-1 RA; disease-modifying for DPN
Disease modification

HbA1c optimisation is the only disease-modifying intervention for DPN. Prevents further progression (DCCT; UKPDS). Mrs. Osei HbA1c 62 (target <53): medication review via diabetes team. SGLT2 inhibitors: also cardiovascular + renal protection — important in DPN (cardiovascular risk marker). Note: rapid glucose improvement can transiently worsen DPN (acute painful neuropathy of rapid control; rare but recognised — warn).

Practical

Diabetes team referral today. Mediterranean diet; reduced refined carbohydrate. Weight management. Regular glucose monitoring. Annual diabetes review: HbA1c; renal function; retinopathy; neuropathy; cardiovascular risk.

HbA1c optimisation: prevents DPN progression; most important disease-modifying intervention
7D — Prescribing guide
NICE CG173 first-line: amitriptyline; duloxetine; gabapentin; or pregabalin. For Mrs. Osei: duloxetine is optimal (dual indication: DPN + depression; PHQ-9 12). Stop ibuprofen (ineffective for neuropathic pain; nephropathy risk in DM).
Step 1 — Duloxetine (Mrs. Osei’s optimal choice)
  • 30mg OD with food for 1 week; increase to 60mg OD at week 2
  • Licensed for DPN (NICE CG173 first-line); dual indication if PHQ-9 ≥10
  • 4–8 weeks for full analgesic and antidepressant effect
  • Monitor BP at 4 weeks; PHQ-9 at 2 weeks and 4 weeks; LFTs at 3 months
  • Taper over minimum 4 weeks on discontinuation (avoid discontinuation syndrome)
4-week review: pain NRS; PHQ-9; tolerability; foot check. If <30% improvement at 8 weeks: add amitriptyline or switch to gabapentinoid.
Alternative Step 1 — Amitriptyline
  • 10mg OD at night; titrate by 10mg every 2 weeks; target 25–50mg
  • Sleep benefit (sedating at low dose) — particularly useful for Mrs. Osei’s night pain
  • Check ECG first (age 67; DM; QTc risk)
  • Supply restrict to 2-week supply if PHQ-9 ≥10 (overdose risk; low TI)
  • Anticholinergic: dry mouth; constipation; urinary retention; fall risk
Can combine amitriptyline 10mg at night with duloxetine if one agent alone is insufficient.
Do NOT prescribe these
  • Tramadol or strong opioids: NOT first-line for neuropathic pain (NICE CG173); harms exceed benefits; do not correct the nerve mechanism
  • NSAIDs or paracetamol alone: ineffective for pure neuropathic pain; NSAIDs worsen nephropathy in DM — stop ibuprofen today
  • Gabapentinoid without checking eGFR: mandatory safety check; prescribing standard dose with eGFR 35 = prescribing error
  • Carbamazepine: first-line for TN only; not for DPN or other neuropathic pain
If duloxetine/amitriptyline inadequate at 8 weeks — gabapentinoid
  • Gabapentin: 300mg OD day 1; 300mg BD day 2; 300mg TDS day 3; titrate to 1800–3600mg/day; Schedule 3 CD; check eGFR first
  • Pregabalin: 75mg BD; titrate to 150mg BD; max 300mg BD; Schedule 3 CD; also licensed for GAD
  • BOTH: 50% dose reduction if eGFR 30–59; 75% if eGFR 15–29
  • Sedation; dizziness; weight gain; fall risk in elderly; taper on discontinuation
PHN-specific topical options
  • Lidocaine 5% plasters (Versatis): PHN only; 1–3 plasters; 12h on / 12h off; intact skin; minimal systemic absorption; safe in elderly
  • Capsaicin 0.075% cream: 3–4 times/day; initial burning; deplete substance P; 4–6 weeks for effect
  • Capsaicin 8% (Qutenza): specialist clinic only; single application; up to 3 months relief
7E — Medication selector

Select patient characteristics — neuropathic pain drug guidance

Neuropathic pain drug guidance
DPN + depression (Mrs. Osei): duloxetine 30mg OD food ×1w → 60mg OD; dual indication; NICE CG173 first-line. DPN without prominent depression: amitriptyline 10mg OD night (check ECG; titrate to 25–50mg) OR gabapentinoid (check eGFR first; Schedule 3 CD). Cardiac concern / QTc >450ms: avoid amitriptyline; prefer duloxetine or gabapentinoid. Renal impairment eGFR <60: dose-reduce gabapentinoid (50% if eGFR 30–59); avoid duloxetine if eGFR <30; amitriptyline preferred. PHN: amitriptyline OR gabapentinoid PLUS topical — lidocaine 5% plasters (Versatis: 3 patches 12h on/12h off; intact skin); capsaicin 0.075% cream 3–4 times/day; Qutenza (specialist). Trigeminal neuralgia: carbamazepine 100mg BD → titrate 400–1200mg/day (NOT amitriptyline or gabapentinoid first-line for TN); monitor Na+; FBC; LFTs. NOT for neuropathic pain: tramadol; strong opioids; NSAIDs; paracetamol alone (NICE CG173).
7F — Drug reference cards
Duloxetine (SNRI)
Cymbalta · 30mg OD food → 60mg OD · DPN licensed · dual: pain + depression · NICE CG173 first-line
✓ First-line DPN with comorbid depression — start 30mg OD with food ×1 week then 60mg OD
NICE CG173 first-line; licensed for DPN30mg OD food ×1w; →60mg OD; max 120mg (specialist); check BP + LFTs before
✓ Why duloxetine for Mrs. Osei
SNRI; serotonin and noradrenaline reuptake inhibition; enhances descending pain inhibitory pathways (locus coeruleus → dorsal horn → reduces afferent pain signal). Dual indication: diabetic peripheral neuropathic pain AND depression (PHQ-9 12). Specifically licensed for DPN in the UK. Start 30mg OD with food for 1 week (reduces nausea); increase to 60mg OD at week 2. 4–8 weeks for full analgesic and antidepressant effect — do not judge at 2 weeks.
✗ Contraindications
Concurrent MAOI (serotonin syndrome — fatal); severe hepatic impairment; eGFR <30 (avoid); uncontrolled hypertension; concurrent linezolid. Caution: bleeding risk (SNRIs impair platelet aggregation — add PPI if concurrent NSAID); mania/bipolar; seizures; pregnancy; angle-closure glaucoma.
⚠ Side effects
Nausea (most common; usually settles after 1–2 weeks; take with food). Dry mouth. Insomnia (morning dosing). Sweating; sexual dysfunction. BP elevation (noradrenergic; monitor BP at 4 weeks). Discontinuation syndrome (taper over ≥4 weeks; “brain zaps”; dizziness). Suicidal ideation first 4 weeks — safety-net and PHQ-9 at 2–4 weeks.
🔬 Monitor
BP at 4 weeks. LFTs at 3 months. PHQ-9 at 2 weeks and 4 weeks (suicidality + depression response). NRS pain score at 4 weeks. Taper over minimum 4 weeks on discontinuation. If no response at 8 weeks at 60mg: consider adding amitriptyline 10mg at night; or switch to gabapentinoid; or pain clinic.
💬 For Mrs. Osei

"I am prescribing a tablet called duloxetine. It works on the nerve pain pathways in your spinal cord — completely different from paracetamol or ibuprofen. It also helps with your mood. Start with 30mg once a day with food for a week, then move up to 60mg. It takes 4 to 8 weeks to feel the full benefit — please don’t stop it at 2 weeks if you still have some pain. I will review you at 4 weeks."

Duloxetine 30mg OD → 60mg OD: NICE CG173 first-line for DPN; dual indication with PHQ-9 ≥10; avoid if eGFR <30 or severe hepatic impairment. 4–8 weeks for effect; taper on discontinuation; monitor BP + PHQ-9. SCA key: choosing duloxetine for Mrs. Osei (DPN + PHQ-9 12) demonstrates understanding of the dual indication — distinguishes strong pass from bare pass.

Amitriptyline (TCA)
10mg OD at night · titrate to 25–75mg · first-line all neuropathic types · sleep benefit · supply restrict if suicidality
✓ First-line all neuropathic types — night dosing; sleep benefit; ECG in cardiac-risk; supply restrict if PHQ-9 ≥10 + suicidality
NICE CG173 first-line — all neuropathic pain types10mg OD night; titrate by 10mg every 2 weeks; target 25–50mg; max 75mg primary care
✓ Mechanism and sleep benefit
Inhibits noradrenaline and serotonin reuptake; enhances descending pain inhibition; sodium channel-blocking properties stabilise ectopic neuronal firing. Sedative effect at low doses (10–25mg) is therapeutically beneficial for patients with night pain and sleep disruption (Mrs. Osei). Take at night (10pm): sedation peaks at bedtime; analgesic effect persists overnight; residual sedation minimal by morning at low doses. Full analgesic effect: 4–6 weeks. Less expensive; longer evidence base than duloxetine.
✗ Contraindications
Recent MI; QTc >450ms (F)/>430ms (M) — check ECG in cardiac-risk patients; angle-closure glaucoma; concurrent MAOI; severe hepatic impairment. Caution: BPH (urinary retention); dementia; epilepsy. SUPPLY RESTRICTION: PHQ-9 ≥10 with any suicidality — prescribe 2-week supply only (amitriptyline has low therapeutic index in overdose; dangerous in intentional overdose).
⚠ Side effects
Anticholinergic: dry mouth (very common); constipation; urinary retention; blurred vision; confusion (especially elderly). Sedation (beneficial at night; warn re driving). Postural hypotension (fall risk — check lying/standing BP). Weight gain. QTc prolongation.
🔬 Monitor
ECG at baseline in cardiac-risk patients. PHQ-9 at 2 weeks (suicidality). BP (postural). NRS pain + DN4 at 4–6 weeks. Titrate before concluding failure — 10mg for 8 weeks without dose increase is not an adequate trial. Switch or add if no response at 8 weeks on 25–50mg.
💬 Counselling

"Take this at around 10 at night — it will help with the nerve pain and also helps with sleep, which is very useful because the pain is worst at night. You may feel a bit drowsy the next morning at first — that usually improves. Your mouth may feel dry. Do not drive until you know how it affects you."

Amitriptyline: NICE CG173 first-line; all neuropathic types; 10mg OD night; titrate to 25–50mg; ECG before in cardiac-risk patients. SUPPLY RESTRICT to 2-week supply if PHQ-9 ≥10 (low therapeutic index — dangerous in overdose). Anticholinergic: dry mouth; fall risk. Can combine with duloxetine (additive mechanism) if single agent insufficient.

Gabapentin
Schedule 3 CD · 300mg OD→BD→TDS titration · renal dose adjustment mandatory · NOT for non-specific LBP (NICE NG59)
✓ First-line neuropathic pain — check eGFR FIRST; Schedule 3 CD; slow titration; dose-reduce in renal impairment
NICE CG173 first-line — all neuropathic types300mg OD day 1; BD day 2; TDS day 3; titrate to 1800–3600mg/day; renal dose-adjust
✓ Mechanism and titration
Binds α2δ subunit of voltage-gated calcium channels; reduces calcium influx and neurotransmitter release from primary afferents; reduces ectopic nerve discharge. Titrate: 300mg OD night → 300mg BD → 300mg TDS (over 3 days); then increase by 300mg every 3–7 days to effective dose (usually 1800mg/day in divided doses; max 3600mg/day). Schedule 3 CD: full CD prescription; 30-day maximum supply.
✗ Renal dose adjustment — MANDATORY
Check eGFR BEFORE prescribing. eGFR >60: standard (max 3600mg/day). eGFR 30–59: max ~1800mg/day. eGFR 15–29: max ~900mg/day. eGFR <15 / dialysis: specialist. NOT for non-specific LBP (NICE NG59) — gabapentin IS appropriate for neuropathic pain but NOT for mechanical back pain. This distinction is frequently tested in the SCA.
⚠ Side effects
Sedation (warn driving; fall risk in elderly). Dizziness; ataxia. Weight gain. Peripheral oedema. Dependence risk (Schedule 3). Withdrawal seizures on abrupt discontinuation — taper always (reduce by no more than 300mg at a time over weekly intervals).
🔬 Monitor
eGFR at baseline and 3 months. Weight. Falls assessment at each visit (“have you had any falls?”). Pain NRS at 4–6 weeks. Taper on discontinuation. Review at 4 weeks: ≥30% pain reduction?
💬 Counselling

"This is a controlled drug that we start at a low dose and build up slowly over a few weeks. It may make you drowsy at first — do not drive until you know how it affects you. It can cause weight gain. If we ever need to stop it, we do so gradually — never all at once."

Gabapentin: NICE CG173 first-line for neuropathic pain; Schedule 3 CD; check eGFR BEFORE prescribing; dose-reduce at eGFR <60; taper on discontinuation. KEY DISTINCTION: gabapentin IS first-line for neuropathic pain (CG173) but NOT recommended for non-specific LBP (NG59) — tested frequently; getting this backwards is a common SCA error.

Pregabalin
Schedule 3 CD · 75mg BD → 150mg BD · faster titration than gabapentin · also licensed for GAD · renal dose-adjust
✓ First-line neuropathic pain — faster titration; licensed also for GAD; Schedule 3 CD; check eGFR
NICE CG173 first-line — may prefer if comorbid GAD75mg BD; titrate to 150mg BD at week 2; max 300mg BD; renal dose-adjust
✓ Advantages over gabapentin
Same mechanism as gabapentin (α2δ calcium channel binding) but more predictable pharmacokinetics (linear absorption; more consistent blood levels). Faster titration: 75mg BD → 150mg BD at week 2 → 300mg BD at week 4 if needed. Licensed for GAD as well as neuropathic pain — useful if both conditions coexist. More predictable dose-response. Disadvantage: Schedule 3 CD; sedation; dependence; higher euphoria rate than gabapentin.
✗ Same renal dose adjustment as gabapentin
eGFR >60: max 600mg/day. eGFR 30–59: max 300mg/day. eGFR 15–29: max 150mg/day. eGFR <15: max 75mg/day. Dialysis: supplement after each session. Schedule 3 CD. High misuse potential — caution if addiction history.
⚠ Side effects
Same class: sedation; dizziness; weight gain; peripheral oedema; dependence; ataxia. Euphoria: higher rate than gabapentin (controlled drug status reflects this). Taper on discontinuation.
🔬 Monitor
eGFR; weight; falls; pain NRS. PHQ-9 + GAD-7 if comorbid anxiety. Taper when stopping. Review at 4 weeks.
💬 Counselling

"This is a controlled drug — similar to gabapentin but twice-a-day dosing and a simpler schedule. It can make you drowsy — do not drive until used to it. We taper it gradually when stopping."

Pregabalin: NICE CG173 first-line; Schedule 3 CD; faster titration than gabapentin; check eGFR before prescribing (same renal dose adjustments); also licensed for GAD. Never prescribe for non-specific LBP (NICE NG59). Misuse potential: higher euphoria rate; caution in addiction history.

Lidocaine 5% Plasters (Versatis)
PHN only · 1–3 plasters · 12h on / 12h off · no systemic side effects · allodynia particularly
✓ PHN with allodynia — topical; no CNS effects; safe in elderly; 12h on / 12h off; intact skin only
PHN specifically — not licensed for DPN1–3 plasters to painful area; 12h on; 12h off; reapply next day; intact skin
✓ Role in post-herpetic neuralgia
Sodium channel blockade in peripheral cutaneous nerve fibres; reduces ectopic discharge and allodynia. Key advantage: minimal systemic absorption (<5% of applied dose) — no CNS sedation; no fall risk; safe in elderly patients where amitriptyline and gabapentinoids cause sedation and falls. Particularly useful for allodynia (when even bedsheets or clothing cause pain). Apply to intact skin only (never broken skin; mucous membranes). Maximum 3 plasters at one time; 12 hours maximum in 24 hours; 12-hour patch-free interval.
✗ Limitations
Licensed for PHN only — not for DPN; central neuropathic pain; or other conditions (though used off-label). Broken; inflamed; or infected skin: do not apply. Local skin reactions (erythema; pruritis) at site — usually mild; rotate sites.
⚠ Minimal systemic side effects
Systemic absorption minimal — main advantage in elderly patients. Local effects only: application site erythema; pruritis. No CNS effects. Can combine with systemic agents for enhanced effect in PHN.
🔬 Monitor
NRS pain at 4 weeks. Skin at application site. Consider adding systemic agent if inadequate response at maximum plaster dose.
💬 Counselling

"These patches contain a local anaesthetic. Apply them to the painful area for 12 hours — usually overnight — and remove them for the next 12 hours. Use up to 3 at a time. Only put them on skin that is not broken or irritated. They work at the nerve endings with minimal effect on the rest of your body."

Lidocaine 5% plasters (Versatis): PHN specific; 1–3 plasters; 12h on / 12h off; intact skin; minimal systemic absorption; safe in elderly (no sedation; no fall risk). Not for DPN (Mrs. Osei’s condition). Particularly useful for allodynia. High-strength capsaicin 8% (Qutenza): specialist clinic; highly effective for PHN.

Carbamazepine
Tegretol · 100mg BD → titrate · FIRST-LINE trigeminal neuralgia ONLY · NOT for DPN or PHN · CYP450 inducer · monitor Na+; FBC; LFTs
✓ Trigeminal neuralgia FIRST-LINE — not first-line for any other neuropathic pain; extensive monitoring required
TN first-line (NOT DPN; NOT PHN; NOT general neuropathic pain)100mg BD; increase by 100–200mg/week; target 400–1200mg/day in divided doses
✓ Trigeminal neuralgia — the specific indication
Carbamazepine is the gold standard for TN: 80–90% initial response rate. Sodium channel blockade reduces hyperexcitability of trigeminal nucleus neurons. Start 100mg BD; increase by 100mg/week to effect; target 400–1200mg/day. Blood levels (therapeutic range 17–50 micromol/L) guide toxicity not dosing — dose by clinical response. CYP3A4/CYP2C9 inducer — reduces warfarin; OCP; tricyclics; statins. If symptom-free at 6–12 months: consider dose reduction trial.
✗ Extensive monitoring requirements
Na+ (SIADH; hyponatraemia — especially elderly): check at baseline and 4 weeks; Na+ <130: stop. FBC (agranulocytosis — rare but fatal; check at baseline + 4 weeks; warn: report fever; sore throat; mouth ulcers immediately). LFTs (hepatotoxicity). ECG (QTc prolongation). Stevens-Johnson syndrome (rare but serious; stop if rash). Drug interactions: extensive (CYP450 inducer — review all medications).
⚠ Side effects
Sedation; dizziness; diplopia (dose-related). Nausea. Hyponatraemia (SIADH; elderly most at risk). Hepatotoxicity. Skin rash (common; mild; Stevens-Johnson rare). Haematological (agranulocytosis; aplastic anaemia — rare). Teratogenic — avoid in pregnancy.
🔬 Monitor
Baseline: FBC; LFTs; Na+; ECG; full drug interaction review. At 4 weeks and 3 months: FBC; LFTs; Na+; TN response. 6-monthly if ongoing. Neurology if refractory; MVD surgery — highly effective and potentially curative.
💬 Counselling

"This tablet is very effective for the type of facial pain you have. We start low and build up. I will do blood tests to monitor your blood count and salt levels. Tell me immediately if you develop a sore throat; a fever; or a rash — because rarely this drug can affect the blood, and that needs prompt attention."

Carbamazepine: FIRST-LINE for trigeminal neuralgia ONLY — not DPN; not PHN. 100mg BD → titrate. Monitor Na+ (SIADH); FBC (agranulocytosis — report fever/sore throat; urgent FBC); LFTs; drug interactions (CYP450 inducer). Neurology if refractory; MVD surgery potentially curative. SCA: prescribing amitriptyline or gabapentin as first-line for TN = Tasks fail.

7G — Psychosocial impact of chronic neuropathic pain
🧑️
Neuropathic pain changes every domain of Mrs. Osei’s life — pharmacology addresses only one part
Chronic neuropathic pain disrupts sleep; limits mobility; generates depression; creates social isolation; threatens identity; and amplifies fear about the underlying disease. Each worsens the pain signal through central sensitisation. Addressing the pharmacological component without addressing these dimensions produces a partial response at best.
🚘
Driving

Sedating medications must be discussed. Amitriptyline: initial sedation; do not drive until established on dose. Gabapentinoids: significant sedation; warn specifically. Duloxetine: less sedating but warn about initial period. DVLA: if medication impairs driving ability the patient must not drive — legal obligation. Document driving advice in notes.

"I need to mention — this medication can make some people drowsy at first. Until you know how it affects you, please do not drive. If you find it is making you drowsy when driving, you must stop using the car — it is a legal as well as a safety requirement."
😊
Social Life and Isolation

Mrs. Osei’s daily walk was her primary social and physical activity. Its loss has isolated her — worsening depression and pain. Social prescribing: chronic pain groups; telephone befriending; adapted exercise classes. The duloxetine will help mood; any restored mobility breaks the isolation cycle.

"I want to think about getting you back to some social contact too. The pain can become very isolating. There are local groups for people managing persistent pain — I can refer you through our social prescribing service."
💔
Relationships and Intimacy

Chronic pain and medication side effects (duloxetine: sexual dysfunction; amitriptyline: same) affect intimacy. The GP who opens this conversation removes the stigma. Information that medications may affect this — and alternatives exist — is practically important.

"Chronic pain can sometimes affect other parts of life — including intimacy with a partner. Is that something that has been a concern? The medication can sometimes affect this too — please let me know if it becomes an issue."
😴
Sleep

Night pain worsens sleep; poor sleep amplifies pain. If duloxetine chosen (morning dosing; may cause insomnia): add low-dose amitriptyline 10mg at night for sleep benefit if needed. Sleep hygiene alongside pharmacological treatment.

"Has the pain been waking you? Poor sleep and pain make each other worse. One reason I am considering the nighttime tablet option is that it also helps sleep — which is part of the pain treatment."
📈
Diabetes Anxiety

Mrs. Osei interprets her pain as evidence of diabetes deteriorating. This catastrophic belief amplifies pain. It must be directly corrected: DPN does not mean imminent amputation; HbA1c optimisation prevents progression; foot care prevents ulceration. Anxiety about diabetes is a driver of depression and pain — addressing the illness model is a pain intervention.

"I want to be clear — this pain does not mean your diabetes is about to cause you to lose your feet. It means the nerves are irritated. With the right treatment and foot care, we can manage this well."
👩‍🏫
Identity and Loss

Retired teacher; active; community-connected — chronic pain threatens this identity. The loss of daily walks removes a key source of independence and self-efficacy. Adapted exercise (chair yoga; swimming) and community groups restore what can be restored alongside pain management.

"I can see this has taken a lot from you — not just the pain, but the walking and the activities. I want us to work together to get you back to as much of that as possible. The medication is the start — not the end."
7H — Follow-up
T
Today — Duloxetine 30mg OD; stop ibuprofen; investigations; referrals; safety-nets given

Duloxetine 30mg OD food; increase to 60mg OD at week 2. Ibuprofen stopped (ineffective + nephropathy risk). eGFR; B12; HbA1c; LFTs; ECG requested. PHQ-9 12; Q9 screened; suicidality safety-net given and documented. Podiatry referral. Diabetes team referral. NHS Talking Therapies referral. Foot care education provided. Driving advice given. DN4 scored and documented. 4-week review booked.

4-week review booked before Mrs. Osei leaves
2
2 Weeks — PHQ-9 suicidality check; duloxetine tolerability; dose increase confirmed

Telephone or face-to-face. Is she tolerating duloxetine? Has nausea settled? Has she been able to increase to 60mg OD? PHQ-9 at 2 weeks (mandatory suicidality monitoring with antidepressant initiation). If Q9 ≥1: urgent face-to-face. Driving status confirmed.

Mandatory: suicidality check; dose increase to 60mg; tolerability
3
4 Weeks — Main review: pain NRS; PHQ-9; DN4; blood results; foot inspection

Face-to-face. NRS pain: ≥30% improvement? PHQ-9: improvement from 12? DN4 re-score. Review bloods. Foot inspection. If ≥30% improvement: continue duloxetine 60mg. If <30%: titrate to 90–120mg (check BP; specialist territory) OR add amitriptyline 10mg at night. If no improvement: switch to gabapentinoid (check eGFR allows dose). Podiatry + diabetes team updates expected.

NRS; PHQ-9; DN4; blood results; foot; titration decision
4
8–12 Weeks — Second agent or pain clinic if needed

If duloxetine 60mg at 8 weeks: inadequate response — add amitriptyline 10mg OD at night OR switch to gabapentinoid (eGFR first). If second agent also inadequate: pain clinic referral. HbA1c review from diabetes team. Annual podiatry. NHS Talking Therapies progress.

Second agent or pain clinic; HbA1c; annual podiatry
5
Annually — DPN; diabetes; mental health; podiatry

Annual diabetes foot check (NICE quality standard). PHQ-9 + GAD-7. NRS pain score. Medication review. eGFR. HbA1c. Retinopathy screening. Pain clinic if complex or refractory.

Annual foot check; PHQ-9; medication review; eGFR; HbA1c
7I — Monitoring — SNAP mnemonic

SNAP monitoring mnemonic for neuropathic pain

Sleep: improved? Sleep quality as proxy for pain control. NRS: 0–10 pain score at every review — ≥30% improvement? Activity: can Mrs. Osei walk further; do more than at first visit? PHQ-9: depression score at every review — pain and depression must be tracked together.

DrugMonitorTimingAction threshold
DuloxetineBP; LFTs; PHQ-9 Q9; NRS painBP + PHQ-9 at 2–4 weeks; LFTs at 3 months; NRS every reviewBP >20mmHg rise: treat or switch. LFTs >3× ULN: stop. Q9 ≥1: urgent review. NRS unchanged at 8 weeks: escalate
AmitriptylineECG; PHQ-9 Q9; BP lying/standing; NRSECG baseline (cardiac-risk); PHQ-9 at 2 weeks; BP at 4 weeksQTc >500ms: stop. Q9 ≥1: urgent + supply restrict. Postural drop >20mmHg: falls risk; reduce dose
GabapentinoidseGFR; weight; falls assessment; NRSeGFR at baseline and 3 months; weight + falls at each revieweGFR fall below threshold: reduce dose. Falls: reduce dose; consider switch. Taper on all discontinuation
Carbamazepine (TN)Na+; FBC; LFTs; TN pain response; drug interactionsNa+; FBC; LFTs at baseline; 4 weeks; 3 months; then 6-monthlyNa+ <130: stop. Agranulocytosis signs (fever; sore throat): stop urgently; FBC. LFTs >3× ULN: stop. Rash: stop (SJS risk)
MilestoneAction
2 weeksPHQ-9 Q9 suicidality; antidepressant tolerability; dose increase to target
4 weeksNRS pain (≥30%?); PHQ-9; DN4 re-score; blood results; foot inspection; titration decision
8–12 weeksIf <30% improvement: second agent or pain clinic referral
AnnuallyAnnual foot check; PHQ-9; HbA1c; eGFR; medication review
7J — Safety-netting

⚠ Three critical safety-nets for Mrs. Osei

🔴 Emergency — foot wound or ascending neurological symptoms
"If you notice any redness; wound; blister; or any area that looks different on either foot — ring the surgery immediately or come today. In diabetes a foot wound can become serious very quickly. Also: if the pain suddenly spreads rapidly upwards; or you develop any numbness between your legs or difficulty with your bladder — go to A&E. Do not wait."
Diabetic foot wound is a medical emergency — delay leads to ulceration; infection; and potential amputation. Ascending neurological symptoms may indicate GBS or cord compression — both emergencies.
💊 Medication — antidepressant initiation and driving
"The medication I am starting today can sometimes affect mood in the first few weeks. If you feel more anxious or have any thoughts of harming yourself — please ring us immediately or go to A&E. Do not stop the tablet suddenly without speaking to me first — we need to reduce it gradually. And please do not drive until you know how the tablet affects you."
NICE requires suicidality safety-net with all antidepressant initiations. Abrupt discontinuation syndrome with duloxetine. Driving impairment from sedating agents.
🟠 Treatment expectations — do not stop early
"The most important message about this tablet is: it takes 4 to 8 weeks to work at the right dose. Please do not stop it at 2 weeks if you still have some pain — it has not had time to work. I will review you in 4 weeks. If the side effects are very troublesome before then, or if the pain is dramatically worse — ring and we will review."
Premature discontinuation is the most common reason first-line agents fail in neuropathic pain. Setting the timeline expectation explicitly prevents this.
999 / same-dayFoot wound; ascending weakness; bladder/bowel change; suicidal crisis
2 weeksPHQ-9 suicidality; duloxetine dose increase to 60mg confirmed
4 weeksNRS pain; PHQ-9; DN4; foot; blood results; titration decision
🎓 SCA Checkpoint — Step 7 (Final)TasksRelating to OthersGlobal Skills
Closing the consultation
"Let me pull together what we have decided. The pain in your feet is called diabetic peripheral neuropathy — the nerves are irritated by years of slightly raised blood sugar and they are misfiring. That is why the paracetamol and ibuprofen have not worked — they treat tissue damage pain, not nerve pain."
"I am prescribing a tablet called duloxetine. It works on the nerve pain pathways and also helps with your mood. Start with 30mg once a day with food, then 60mg after a week. It takes 4 to 8 weeks to feel the full benefit — please do not stop it at 2 weeks if you still have some pain."
"I am stopping the ibuprofen — it is not helping your pain and over time it can affect your kidneys. I am referring you to the podiatrist and to the diabetes nurse about your blood sugar levels."
"I want to address the worry about your feet directly: DPN does not mean you are going to lose your feet. What causes amputations in diabetes is foot wounds that become infected — and we are going to prevent that with the podiatry referral and the foot care advice I am giving you today."
"Two important safety messages: if you see any redness or wound on your feet, contact us that day. And if you feel more anxious or have any dark thoughts after starting the tablet, ring us immediately or go to A&E. Before you go — is there anything we haven’t covered?"
Deductions
  • Prescribing tramadol or opioids as the next step — not first-line for neuropathic pain; treats the wrong mechanism
  • Prescribing gabapentinoid without checking eGFR — mandatory safety check
  • Not explaining why NSAIDs and paracetamol failed — without this explanation Mrs. Osei has no reason to persist with a different drug
  • Not setting the 30–50% reduction expectation over 4–8 weeks — will lead to premature discontinuation
  • Not addressing the amputation fear — the most likely hidden concern; leaving it unresolved
  • Not checking PHQ-9 Q9 suicidality when initiating an antidepressant with PHQ-9 12
  • Carbamazepine as first-line for DPN — carbamazepine is for TN only
Tasks — summary
  • DPN diagnosed; DN4 scored; mechanism explained
  • PHQ-9 12; Q9 suicidality screened; documented
  • Duloxetine prescribed (dual indication; correct dose; titration plan)
  • NSAIDs stopped with rationale
  • eGFR checked (before prescribing; even if gabapentinoid not chosen)
  • Podiatry + diabetes team + NHS Talking Therapies referred
  • 4-week review booked; expectations set
Relating to Others
  • Distress acknowledged first
  • Why NSAIDs fail — plain language explanation
  • Amputation fear raised and addressed directly
  • 30–50% expectation set honestly
  • Depression dual-treatment explained
  • Antidepressant suicidality safety-net
  • Driving advice given
🔴 Red
Opioids prescribed; NSAIDs continued; eGFR not checked; why NSAIDs fail unexplained; amputation fear unaddressed; PHQ-9 not scored; Q9 not checked; no podiatry; treatment timeline not set; suicidality safety-net absent
🟠 Amber
Duloxetine correctly prescribed; eGFR checked; NSAIDs stopped; PHQ-9 scored; suicidality checked; amputation fear not raised; why NSAIDs fail unexplained; 30–50% expectation not set; podiatry not referred
🟩 Green
Distress acknowledged; DN4 scored; DPN mechanism plain language; why NSAIDs fail explained; duloxetine (dual indication) + titration; eGFR checked; NSAIDs stopped; PHQ-9 12 + Q9 screened + suicidality safety-net documented; amputation fear directly addressed; podiatry + diabetes team + NHS Talking Therapies; 30–50% expectation over 4–8 weeks; foot inspection + care education; driving advice; 4-week review booked; closing question
Neuropathic Pain — SCA Consultation Scorecard
NICE CG173 · DN4 ≥4 · Duloxetine dual indication · NOT opioids · Check eGFR first · 30–50% expectation · Amputation fear · PHQ-9 Q9
0/ 33 pts
🌐
Global Skills
Structure, person-centred approach, safety
0/7
Tasks
Clinical reasoning, prescribing, management
0/15
🤝
Relating to Others
Empathy, communication, shared decision-making
0/11
RAG Self-Assessment
🔴 Red
Opioids prescribed; NSAIDs continued; eGFR not checked; why NSAIDs fail unexplained; amputation fear unaddressed; PHQ-9 not administered; Q9 suicidality unchecked; no podiatry; treatment timeline not set
🟠 Amber
Duloxetine prescribed; eGFR checked; NSAIDs stopped; PHQ-9 scored + Q9 checked; suicidality safety-net given; amputation fear not raised; why NSAIDs fail unexplained; 30–50% expectation not set; podiatry not referred
🟩 Green
All: distress acknowledged; DN4; DPN mechanism plain language; why NSAIDs fail; duloxetine dual indication + titration; eGFR; NSAIDs stopped; PHQ-9 12 + Q9 + suicidality safety-net; amputation fear addressed; podiatry + diabetes team + NHS Talking Therapies; 30–50% over 4–8 weeks; foot inspection + care education; driving advice; 4-week review; closing question
011172533
Fail
Borderline
Pass
Strong pass
📋
Complete the checklist to see your score and feedback
"I’ve had this burning pain in my feet for 6 months now and it’s getting worse. I’ve been taking paracetamol and ibuprofen every day for 3 months and they’re not doing anything. I just need something that actually works. Is there anything you can do?"
Who you are

Patricia Osei, 67, retired secondary school teacher (English). Type 2 diabetes for 12 years; HbA1c 62 at last check 3 months ago; on metformin 1g BD and sitagliptin 100mg OD. Bilateral burning foot pain for 6 months, worse at night, stopping sleep. “Like walking on hot coals” with intermittent electric shock sensations. Cannot do daily walks any more — used to walk 45 minutes every morning. Tearful, frustrated, not sleeping properly. PHQ-9 12.

Hidden agenda — disclose if GP creates space

Amputation fear (disclose if GP asks about your worries specifically): “The thing is — my friend Margaret had diabetes and she lost her foot. I’m frightened that is where this is heading. I haven’t wanted to say it but that’s what worries me most.” Respond well if GP explains the difference between DPN and foot ulceration: “Oh — I didn’t realise they were different things. That is actually very reassuring.”

Self-blame (disclose if asked about how you feel about your diabetes): “I feel like I should have managed my diabetes better. Maybe if I’d been stricter about my diet this wouldn’t have happened.” Respond well if GP addresses this without blame: “Thank you for saying that — I’ve been carrying a lot of guilt.”

Sleep desperation (volunteer if asked about impact): “I am not sleeping properly. The pain wakes me up at 2 or 3 in the morning. I am exhausted.”

Responses to key conversations
  • On why NSAIDs fail: initially surprised: “But they’re painkillers — I thought that meant they worked on any pain?” — respond well if GP explains the mechanism: “I hadn’t thought of it like that — so there are different types of pain?”
  • On duloxetine being an “antidepressant”: may be reluctant: “I don’t want to take an antidepressant — I don’t think I’m depressed.” — respond well if GP explains dual indication: “So it works on the nerve pain as well? Not just the mood? OK, I am more comfortable with that.”
  • On treatment timeline: concerned: “4 to 8 weeks — that seems a long time to still be in pain.” — respond well if GP acknowledges this and explains why: “I suppose if it’s actually going to work properly that is worth waiting for.”
  • On stopping the ibuprofen: initially worried: “But won’t that leave me with nothing for the pain?” — respond well if GP explains why and the new mechanism: “OK — if it’s not doing anything anyway and it could affect my kidneys, there’s not much point taking it.”
Clinical details
  • Age 67; bilateral burning feet ×6 months; worse at night; DN4 score ≥4 (burning; electric shocks; pins and needles; touch sensitivity)
  • Paracetamol 1g QDS + ibuprofen 400mg TDS ×3 months — no benefit
  • PHQ-9 12 (moderate depression); Q9 = 0 (no suicidal ideation at this appointment)
  • Monofilament: reduced protective sensation bilaterally (2–3 sites per foot)
  • Foot inspection: no active ulcer; mild dry skin; no callus requiring urgent podiatry
  • DM ×12y; HbA1c 62; metformin 1g BD; sitagliptin 100mg OD; no cardiac history
  • eGFR: will come back as approximately 68 mL/min/1.73m² (mildly reduced; no dose adjustment needed for standard duloxetine)
"I’ve been taking painkillers every day for 3 months and they are not doing anything. Is there anything that actually works for this? I am desperate. I am not sleeping. I feel terrible. Can you give me something stronger?"

Resolution: Mrs. Osei accepts the plan if the GP: explains why paracetamol and ibuprofen do not work for nerve pain (not dismissed but explained specifically); prescribes duloxetine with a clear explanation of both why it helps pain AND mood; addresses the amputation fear directly; sets honest expectations (30–50% reduction over 4–8 weeks); and refers to podiatry and the diabetes team. She leaves saying: “I hadn’t realised there were drugs specifically for nerve pain. And knowing that it’s not necessarily going to end up like what happened to Margaret — that is the most reassuring thing you’ve said today.”

🏥
Clinic Quick Reference
Neuropathic Pain — Clinical Decision Framework
NICE CG173 · DN4 ≥4/10 · First-line: amitriptyline; duloxetine; gabapentin; pregabalin · NOT NSAIDs · NOT opioids · Check eGFR · TN = carbamazepine
expand
💊 1 — Classification and Action
Neuropathic pain → Screen: emergency? (CES; GBS; cord compression) → Urgent? (shingles <72h; rapidly progressive) → GP-managed?
🔴 Emergency
  • CES: saddle numbness + bladder/bowel → 999 + emergency MRI
  • GBS: ascending weakness + sensory loss → 999 + hospital + IVIG
  • Cord compression (cancer) → same-day + dexamethasone
999 or same-day hospital
🟠 Urgent
  • Shingles <72h of rash → antiviral; ophthalmology if eye
  • Rapidly progressive or asymmetric neuropathy → neurology; NCS; vasculitis screen
Days to 2 weeks
🟩 GP-managed
  • DPN (Mrs. Osei): DN4 ≥4; duloxetine or amitriptyline; eGFR; HbA1c; podiatry
  • PHN: amitriptyline; gabapentinoid; lidocaine patches; capsaicin
  • TN: carbamazepine (NOT amitriptyline/gabapentin first-line)
NICE CG173 first-line drugs
📋 2 — Key Clinical Numbers
DN4 ≥4/10
Validated neuropathic pain screening: sensitivity 83%; specificity 90%. Document at baseline; re-score at 4 weeks (≥2-point improvement = clinically meaningful)
30–50% reduction
Treatment target: not elimination. Aim for 30–50% pain reduction (NRS 8/10 → 4/10). Explain to patient at outset; prevents premature discontinuation at 2 weeks
4–8 weeks
Time to full analgesic effect for amitriptyline; duloxetine; gabapentinoids. Titrate before judging failure. Adequate trial at adequate dose before switching.
eGFR before CD
Check eGFR BEFORE gabapentin or pregabalin. eGFR <60: reduce dose 50%. eGFR <30: specialist. Prescribing standard dose with eGFR 35 = prescribing error
NOT NSAIDs/opioids
NSAIDs and paracetamol are NOT effective for pure neuropathic pain (wrong mechanism). Opioids not first-line (NICE CG173). Do not escalate the analgesic ladder — switch class
TN: carbamazepine
Trigeminal neuralgia: carbamazepine first-line (NOT amitriptyline/gabapentin). Monitor Na+ (SIADH); FBC (agranulocytosis); LFTs; CYP450 interactions
Versatis: 3 patches 12h
Lidocaine 5% plasters (PHN only): max 3 plasters for 12 hours in 24; 12h off; intact skin; minimal systemic absorption; safe in elderly (no sedation)
PHQ-9 every review
Depression co-exists in 30–60% of chronic neuropathic pain. PHQ-9 at every review; Q9 suicidality specifically; duloxetine dual indication if PHQ-9 ≥10 + DPN
Amitriptyline at 10pm
Night dosing maximises sleep benefit; minimises residual morning sedation; analgesic effect persists overnight. Supply restrict to 2-week supply if PHQ-9 ≥10 (overdose risk)
ECG before amitriptyline
In cardiac-risk patients (age >65; DM; known cardiac history): check QTc before amitriptyline. QTc >450ms (F)/>430ms (M): avoid TCA; prefer duloxetine or gabapentinoid
B12: metformin risk
Metformin reduces B12 absorption. Check B12 in all DPN patients on long-term metformin. B12 deficiency can mimic or worsen DPN. Replace if <150 pg/mL.
HbA1c: disease-modifying
HbA1c optimisation prevents DPN progression (DCCT/UKPDS: 60% risk reduction). HbA1c target <53 mmol/mol on oral agents. Diabetes team referral for HbA1c above target.
⚠ 3 — SNAP Monitoring
SNAPParameterTimingAction
S — SleepSleep quality; hours; pain awakeningsEvery reviewNot improving: consider adding amitriptyline 10mg at night (if duloxetine chosen). Sleep hygiene education.
N — NRSPain score 0–10; DN4 re-scoreEvery review; DN4 at 4 weeks<30% improvement at 8 weeks on adequate dose: second agent or pain clinic. ≥30%: continue; optimise.
A — ActivityWalking distance; function; activities restoredEvery reviewNo functional improvement: NHS Talking Therapies; adapted exercise prescription; social prescribing. Assess for fear avoidance.
P — PHQ-9PHQ-9 total; Q9 suicidality specifically2 weeks (antidepressant initiation); then every reviewQ9 ≥1: urgent mental health assessment. PHQ-9 not improving: review NHS Talking Therapies engagement; increase antidepressant dose; psychology referral.
🎓
SCA Exam Quick Reference
Neuropathic Pain SCA — DN4 ≥4 · Duloxetine dual · NOT opioids · Why NSAIDs fail · 30–50% expectation · Amputation fear · PHQ-9 Q9
NICE CG173 · Check eGFR · TN = carbamazepine · PHN = Versatis · Mrs. Osei: duloxetine (DPN + PHQ-9 12)
expand
💬 Opening & ICE
Opener: “I can see this has been really wearing you down. Six months of pain stopping you sleeping — that takes a real toll. Before I ask specific questions, tell me in your own words what this pain has been like.”
ICE — Ideas: “What do you think is causing this pain? What is your understanding of what is happening with your diabetes?” Then: “DPN means the nerves are irritated by years of raised blood sugar. The pain itself does not mean your diabetes is suddenly much worse.”
ICE — Concerns: “What worries you most?” If not raised: “I want to ask directly — are you frightened about losing your feet?” Then: “DPN does not mean you are going to lose your feet. Amputation happens from infected foot wounds — not from nerve pain. You don’t have foot wounds right now. Podiatry referral today is our prevention.”
ICE — Expectations: “I completely understand the frustration — 3 months of tablets that haven’t helped. Let me explain why they haven’t worked — and what we are doing differently.”
Why NSAIDs fail — the critical explanation: “Paracetamol and ibuprofen treat tissue damage pain — inflammation and prostaglandins. Your pain is coming from nerves misfiring — not tissue damage. These drugs act on the wrong pathway. The new tablet works on nerve pain pathways in the spinal cord — a completely different mechanism.”
Duloxetine dual indication: “I am choosing this particular medication because it helps with both the nerve pain and your mood. The pain and the low mood feed each other. One medication addressing both is genuinely better than two separate prescriptions.”
30–50% expectation: “The target is a 30 to 50 percent reduction — not complete elimination. If you are at 8/10 now, the goal is 4/10. It takes 4–8 weeks. Please do not stop it at 2 weeks.”
✅ Key SCA Tasks (15pt)
DPN diagnosed; DN4 scored; documented (2pt): DN4 ≥4/10 confirmed; bilateral stocking; DM ×12y; HbA1c 62; monofilament reduced; NSAIDs failed; foot inspection: no active ulcer. DN4 score documented at baseline.
Duloxetine prescribed correctly (2pt): 30mg OD food ×1 week → 60mg OD; dual indication (DPN + PHQ-9 12); titration plan explained; 4-week review booked. Not tramadol; not opioids; not NSAIDs.
NSAIDs stopped with rationale (2pt): Ibuprofen stopped: (1) ineffective for neuropathic pain; (2) nephropathy risk in DM. Mechanism explained to patient. Prescribing tramadol or escalating analgesic ladder = Tasks fail.
PHQ-9 12 + Q9 suicidality (2pt): PHQ-9 12 recognised and acted upon (duloxetine dual; NHS Talking Therapies; 2-week suicidality review). Q9 specifically asked; response documented. If Q9 ≥1: urgent mental health; supply restrict amitriptyline.
eGFR checked before prescribing (2pt): Even if duloxetine chosen — important in DM ×12y (nephropathy risk). B12 checked (metformin depletion). ECG checked (age 67; DM; QTc). LFTs checked (duloxetine). HbA1c reviewed.
Podiatry + foot care education today (1pt): Podiatry referral made. Basic foot care given today: daily inspection; no barefoot; report wounds immediately.
Diabetes team referral — HbA1c optimisation (1pt): HbA1c 62 (target <53): diabetes team/DSN referral. Disease-modifying for DPN.
4-week review + escalation plan (1pt): Specific review date booked. Escalation: if <30% improvement at 8 weeks — add amitriptyline or switch to gabapentinoid; if two agents fail — pain clinic.
Driving advice documented (1pt): Do not drive until medication established and effect known.
Amputation fear addressed (1pt): Named directly; accurate explanation (DPN vs ulceration); podiatry as prevention.
🔴 Opioids (tramadol; codeine) as first-line for neuropathic pain = automatic Tasks fail
🔴 Gabapentinoid without checking eGFR = prescribing error = Tasks fail
🔴 Carbamazepine as first-line for DPN = Tasks fail (carbamazepine = TN only)
👥 Relating to Others (11pt)
Distress acknowledged (1pt): Tearfulness; sleep loss; loss of walking — named specifically
ICE: Ideas — illness model (1pt): “Diabetes getting worse” model corrected with accurate explanation
ICE: Concerns — amputation fear (1pt): Raised directly; DPN vs ulceration explained; podiatry as active prevention
ICE: Expectations — frustration validated (1pt): 3 months of wrong drug acknowledged; new mechanism offered with rationale
Why NSAIDs fail — plain language (1pt): Tissue damage pain vs nerve pain — different pathways; specific explanation not just “they don’t work”
Duloxetine mechanism (1pt): “Turns down the pain volume in the spinal cord; also helps mood” — no jargon
Depression with compassion (1pt): PHQ-9 acknowledged; not just a score — explained as interrelated with pain; dual treatment rationale
30–50% honest expectation (1pt): Not complete elimination; specific numbers; timeline; why this level of improvement matters
HbA1c as empowerment not blame (1pt): “What we can do together” not “you should have managed your diabetes better”
Foot safety-net specifically (1pt): Named symptoms (redness; wound; blister); specific action (ring or come that day); not generic
Closing question + pause (1pt): Genuine 3–5 second pause; Mrs. Osei may ask about paracetamol; diet; permanence of pain
🟩 Mrs. Osei leaves: “I hadn’t realised there were drugs specifically for nerve pain. Knowing it’s not necessarily going to end up like what happened to Margaret — that is the most reassuring thing you said today.”
💊 Drug Quick-Pick
Reviewed: July 2026 · citations verified against current NICE / UK guidance